Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maplirpacept in advanced hematologic malignancies
NCT03530683Phase 1Terminated
- Sponsor
- Pfizer
- Start
- May 2018
- Primary completion
- Jul 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of maplirpacept in lymphoma, multiple myeloma (MM), acute myeloid leukemia (AML) and 1 more (6 arms), sponsored by Pfizer. Primary endpoints: Number of adverse events (AE) by severity at 30 months, Number of participants with Dose-Limiting Toxicities and 3 more. Started May 2018; status: terminated.
02
Drugs
maplirpacept
03
Conditions
lymphomamultiple myeloma (MM)acute myeloid leukemia (AML)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03530683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03530683.